Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA received a positive opinion ...

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, ...

Year-to-date money raised in public, private and other financings of biopharma companies. Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the ...

Edwards Lifesciences Corp. raised its full-year 2026 guidance after seeing strong sales in the first quarter, particulalry ...

Jiangsu Carephar Pharmaceutical Co. Ltd. has patented angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the treatment of depression, bipolar disorder, ...

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals Inc.’s DB-OTO, an AAV-mediated gene ...

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing ...

Actionable intelligence on advances in medical devices and technologies for 20+ years ...

Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to ...

Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a positive primary analysis from its registrational trial, KYSA-8, of ...